Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Kenji Yamao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2849-7779; OpenAlex author ID A5078761490, A5152889217. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2011: 6 papers · 2012: 2 papers · 2013: 6 papers · 2014: none · 2015: 2 papers · 2016: 7 papers · 2017: 3 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 30

  1. Endoscopic ultrasound-guided fiducial marker placement for image-guided proton beam therapy in pancreatic cancer: implications for positional accuracy and posi… Co-author DOI 10.1093/jrr/rrag082↗
  2. Endoscopic Ultrasound Can Differentiate High-Grade Pancreatic Intraepithelial Neoplasia, Small Pancreatic Ductal Adenocarcinoma, and Benign Stenosis. Co-author DOI 10.5009/gnl220521↗
  3. Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report. Last author DOI 10.2169/internalmedicine.4456-20↗
  4. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0233782↗
  5. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗
  6. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  7. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  8. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Last author DOI 10.1016/j.ejca.2015.11.002↗
  9. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Last author DOI 10.1016/j.pan.2016.04.007↗
  10. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Last author DOI 10.1016/j.pan.2016.05.007↗
  11. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. Last author DOI 10.1097/mpa.0000000000000446↗
  12. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  13. The role of endoscopic ultrasound in pancreatic cancer screening. Last author DOI 10.4103/2303-9027.175876↗
  14. Clinical impact of preoperative endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma. Last author DOI 10.4103/2303-9027.180472↗
  15. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  16. [The clinical practice for the diagnosis of pancreatic cancer]. Last author PMID 25856997↗
  17. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancrea… First author DOI 10.1007/s00535-012-0664-2↗
  18. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2012.03.059↗
  19. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. Co-author DOI 10.1186/1479-5876-11-291↗
  20. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  21. Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Last author DOI 10.3389/fphys.2013.00269↗
  22. Cigarette smoking and pancreatic cancer risk: a revisit with an assessment of the nicotine dependence phenotype. Co-author DOI 10.7314/apjcp.2013.14.7.4409↗
  23. Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis. Co-author DOI 10.1155/2012/510397↗
  24. Selected polymorphisms of base excision repair genes and pancreatic cancer risk in Japanese. Co-author DOI 10.2188/jea.je20120010↗
  25. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyr090↗
  26. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2010.01810.x↗
  27. ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Co-author DOI 10.1111/j.1349-7006.2011.01907.x↗
  28. The prognosis of patients with pancreatic cancer is extremely poor. Preface. First author DOI 10.1159/000323476↗
  29. Current concept of endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Last author DOI 10.1159/000323502↗
  30. Interaction between IGF-1 polymorphisms and overweight for the risk of pancreatic cancer in Japanese. Co-author PMID 22199998↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nobumasa Mizuno · 15 shared papers, 2011–2016 · strength 0.61
  2. Kentaro Yamao · 2 shared papers, 2024–2026 · strength 0.45
  3. Kazuo Hara · 9 shared papers, 2011–2020 · strength 0.45
  4. Hiroshi Imaoka · 8 shared papers, 2013–2017 · strength 0.39
  5. Susumu Hijioka · 8 shared papers, 2011–2016 · strength 0.36
  6. Kazunori Takeuchi · 1 shared paper, 2026 · strength 0.25
  7. Tadashi Iida · 1 shared paper, 2026 · strength 0.25
  8. Takuya Ishikawa · 1 shared paper, 2026 · strength 0.25
  9. Takeshi Yanagi · 1 shared paper, 2026 · strength 0.25
  10. Hiroki Kawashima · 1 shared paper, 2026 · strength 0.25
  11. Yasuyuki Mizutani · 1 shared paper, 2026 · strength 0.25
  12. Reiko Ashida · 1 shared paper, 2026 · strength 0.25
  13. Yoshihisa Takada · 1 shared paper, 2026 · strength 0.25
  14. Takuji Okusaka · 7 shared papers, 2011–2017 · strength 0.25
  15. Keitaro Matsuo · 6 shared papers, 2011–2020 · strength 0.22
  16. Shinichi Ohkawa · 6 shared papers, 2011–2017 · strength 0.22
  17. Narikazu Boku · 6 shared papers, 2011–2017 · strength 0.22
  18. Junji Furuse · 6 shared papers, 2011–2017 · strength 0.21
  19. Yasushi Yatabe · 7 shared papers, 2011–2013 · strength 0.20
  20. Jun Nakahodo · 1 shared paper, 2024 · strength 0.20
  21. Ryota Sagami · 1 shared paper, 2024 · strength 0.20
  22. Kazunari Murakami · 1 shared paper, 2024 · strength 0.20
  23. Shinichi Egawa · 4 shared papers, 2013–2017 · strength 0.19
  24. Masao Tanaka · 4 shared papers, 2013–2017 · strength 0.19
  25. Nobuhiro Hieda · 3 shared papers, 2015–2016 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.